• Active immunization with immunogenic conjugates of psychotomimetic small molecules with haptenic properties and with immunogenic proteins implicated in the etiology of schizophrenia may be used in the treatment of this disorder. • Antibodies against enzymes, such as indolethylamine-N-methy ltransferase, may have therapeutic use. • Antibodies against post-synaptic membranes may be used as specific blockers of neurotransmitter receptors. • 'Protecting' antibodies may have a therapeutic effect in certain schizophrenics. • Active immunization with immunogenic conjugates of narcotics may be used as narcotic-antagonists. If the biological factors in a psychiatric illness involve an abnormality in specific sites in the CNS, a therapeutic agent which selectively and specifically acts upon these abnormal sites would be the treatment of choice.
To the extent that the presence of an abnormal compound is involved in the etiology of mental illness (16, 47) , a treatment bringing about the elimination of this compound or its neutralization, with no additional effects, is theoretically the ideal specific procedure.
To the extent that deficiency in a normally present compound is involved in the etiology of certain psychiatric illnesses, the addition of the deficient compound is 513 Can. Psychiatr. Assoc. J. Vol. 20 (1975) Major advances have been made during the last decade in the development of more efficient drugs for the treatment of mental illness, but the effects are only partly specific and their use is associated with many undesirable side effects. It is proposed that for the development of specific biological treatment modalities for mental illness, consideration should be given to the possible use of psychoactive compounds significantly different from those developed previously, particularly, in their promise for specificity.
Recent development of immunogenic conjugates of psychoactive compounds for the production of antibodies which can specifically neutralize the respective drug, and the use of immunological approaches for influencing the function of the central nervous system (CNS) , seem to indicate that one avenue deserving evaluation is the possible use of these approaches in the treatment of mental illness. The high specificity of immunological mechanisms suggests that it may be possible to achieve high specificity in the treatment of mental illness through immunological methods, but it should be stressed that only extensive research will clarify whether these approaches will prove to be feasible, safe and effective. The following hypotheses are proposed: likely to be the ideal treatment. The major psychiatric drugs presently in use do not fit this ideal model and are only partly specific.
Although it is possible that the antipsychotic effects of phenothiazines, as well as their extrapyramydal side effects, are related to their specific effects on the dopaminergic system (27) , these drugs also have a wide range of effects on many biological systems. Chlorpromazine has a general inhibitory effect on permeability of biological membranes and it affects a variety of enzymatic processes, such as the uncoupling of oxidative phosphorylation and inhibition of ATP-ase (17) . It is not surprising that they cause undesirable side effects on the CNS and on other systems and organs.
Based on available knowledge, it is assumed that drug-receptor sites and neurotransmitter-receptor sites, such as morphine-receptors and acetylocholinereceptors are templates of the respective' drug or neurotransmitter (30) .
An antibody directed against an antigenic site is also thought to act as a template into which the antigen is 'fitting' (4). This fitting (both in the case of drug-receptors and neurotransmitter-receptors and in the case of the antibody) may be perceived in terms of conformational complementation (the key and the key-hole model) as well as electrical-charge complementation (opposition of opposite charges on the receptor and drug, and on the antigen and antibody, respectively) .
Thus, Sela et al . found that the overall electrical charge of an antibody is opposite to the electrical charge of the immunogen in the case of electrically-charged immunogens (36) .
In recent years, methods have been developed for the preparation of immunogenic conjugates of various drugs and neurotransmitters with proteins and other macromolecular carriers. These include: serotonin (32), norepinephrine (37), lysergic acid (43) , morphine and its congeners (38) , psychotomimetic indolethylamine, such as 5-methoxy-N-dimethyltryptamine (40, 43) and psychotomimetic catecho-lamines, such as mescaline and 3, 4-dimethoxyphenyl-ethylamine (42) . In experimental animals these immunogenic conjugates produced antibodies against the drug or neurotransmitter which blocked the in vivo or in vitro physiological and pharmacological effects of the drugs and neurotransmitters. Thus, in vitro (45) and in vivo (2) effects of morphine, as well as in vivo effects of serotonin (32) , LSD 25 (44) and 5-methoxy-N-dimethlytryptamine (40) were blocked by their respective specific antibodies. These observations suggest the possibility that active and passive immunization may be used in the treatment of certain psychiatric illnesses where it is desirable to neutralize the effects of compounds with antigenic or haptenic properties and which may be involved in the pathogenesis of certain psychiatric illnesses.
For example, psychotomimetic-methylated indolethylamine may be present in the blood of certain schizophrenic people while they are acutely psychotic (25) . It may be possible to block the effect of these psychotomimetic indolethylamine by active immunization of certain schizophrenic individuals with an immunogenic conjugate of the respective psychotomimetic indolethylamine (40) .
Psychotomimetic catecholamines have also been implicated in the etiology of schizophrenia (14) , and a similar active immunization using appropriate immunogenic conjugates of psychotomimetic catecholamines may be used in the treatment of schizophrenics who do show increased amounts of psychotomimetic catecholamines in their biological materials while acutely psychotic.
Such an active immunization procedure may lead to production of antibodies which will neutralize the respective psychotomimetic compounds in the blood, thus preventing them from reaching the eNS and acting upon it (40) .
Similarly, active immunization with immunogenic conjugates of dependencyinducing drugs, such as morphine, may be used as long-acting antagonists in the treatment of narcotic addiction. The an-tibodies to morphine, which may be produced by the immunization, are expected to bind the exogenously administered morphine or morphine-congener and to prevent it from reaching the CNS. Passive administration of heterologous antibodies to drugs with haptenic properties may, on certain occasions, be used in the treatment of drug-intoxication. Such antibodies may be administered into the blood or the cerebrospinal fluid (CSF). However, the potential production of foreign-protein induced complications, such as serum sickness, will obviously limit the possible therapeutic use of heterologous antibodies.
Another possible limitation to the efficacy of the above described therapeutic use of antibodies to haptenic psychoactive compounds is the existence of a blood-CSF barrier to immunoglobulins (9, 41) .
In healthy humans the CSF IgG is derived, probably exclusively, from the serum with the CSF IgG to serum IgG ratio being 1:385 (41) . Thus, it is likely that only a small fraction of I. V. administered, or in vivo produced antibodies will reach the CSF and CNS.
Administration of antibodies into the CSF may be associated with increased concentration in the CNS inasmuch as diffusion of macromolecules between CSF and CNS has been demonstrated (6, 31) . However, it should be stressed that the blocking of the effect of psychotomimetic haptens by antibodies in the serum may not require any direct access of the antibody to the CSF or CNS. Similar to the mechanism involved in the therapeutic use of hemodialysis and hemoadsorption in intoxication by barbiturates and other hypnotics acting on the CNS (28, 32) , the blocking of the CNS active haptenic compounds by their specific antibodies in the blood is expected to depend on binding and neutralization of the hapten-drug in the blood influencing the equilibrium of the blood-CNS drug concentration.
Various abnormal proteins have been implicated in the etiology of schizophrenia (13, 15) . Administration of intact heterologous antibodies to such proteins may lead to their precipitation and kidney damage. However, pretreatment of the appropriate antibodies with papain may produce Fab fragments (39) which will react with and possibly block the effects of the abnormal proteins but will not induce precipitation. Again, however, the complications involved with administration of heterologous proteins may prohibit or, at best, limit the use of such a treatment approach.
Homologous antibodies to microsomal fraction of liver and brain were found to extinguish specific learned behaviour in rats (22) . Antibodies against CNS antigenic determinants may alter brain function in a specific manner. Thus, Mihailovic and· Jankovic found that antisera produced against the hippocampus of the cat altered the EEG in the hippocampus, but not in the caudate nucleus (24) .
It is conceivable that antibodies against specific neurotransmitter-receptors may specifically alter the activity of the brain sites where these receptors are located, without significantly affecting other areas in the CNS. Antibodies may be specific to antigenic determinants up to a size of approximately 700 A2 for certain antigens, antibodies may be specific for an antigenic determinant of approximately 2,000 A 2 (10) . For example, the area square of the receptor site for acetylocholine is about 100 A2 (30) . If it were possible to fractionate and separate, in a relatively pure form, the receptor sites of acetylcholine which will include adjacent areas of the post-synaptic membrane, one could conceivably produce specific antibodies against the specific receptor, as well as the immediate area on the post-synaptic membrane adjacent to the receptor.
One possible method which can be used in order to obtain specific antibodies directed against the receptor site and the adjacent area of a specific neurotransmitter in a specific anatomical CNS localization may include preparation of a synaptosomal fraction (46) and enzymatic cleavage to polypeptide units by established methods (23) . The mixture of polypeptides thus obtained from the synaptosomal fraction can be purified and the polypeptide frac-tion containing the receptor site of acetylocholine separated by affinitychromatography (35) .
On theoretical grounds, it may be possible to produce an antibody specific to the receptor and the adjacent approximately 600 A2. The specificity of the drug and neurotransmitter receptors in the CNS may be related to partial similarity, as well as partial dissimilarity, of the receptors to a certain neurotransmitter (acetylcholine, for example) in various areas of the CNS. Thus, it is conceivable that antibodies against acetylcholine receptor sites isolated from one area in the CNS (caudate nucleus, for example) can be produced. The greater the surface area of the antigenic determinant, the greater will be the possibility of a lack of considerable cross-reaction. This is illustrated schematically in Figure (b 1) Hypothetical schematic structure of the adjacent part of the post-synaptic membrane in the hippocampus. (Note: significant difference as compared to "b"). (c) Non-antibody antagonist of acetylcholine is specific to receptor "a" but has enough "fitness" to "a1" to be able to block receptor "a1" as well as receptor "a". Antibody "d", however, will be able to block receptor "a" only and not "a1" because of the significant structural difference between area "b" and "b!" of the post-synaptic membrane.
It is well known that various areas of the CNS have relative specific functions. Thus, the caudate nucleus, for example, is associated with extrapyramidal motor activity, while the hippocampus is associated with immediate memory (8) . If it were possible to obtain antibodies which could specifically block neurotransmitterreceptors in selected areas of the CNS, it would be possible to influence behaviour, as well as alter psychopathology in a specific manner, while minimizing undesirable side effects associated with the use of drugs which block receptor sites with relatively limited specificity and selectivity.
As Paton indicates, knowledge of the structure of drug receptors and neurotransmitter receptors is incomplete (30) . The receptor for acetylcholine had been studied more extensively than other neurotransmitter-receptors and some of the studies on the isolated acetylcholine receptor indicate that the receptor is homogenous in chemical characteristics and probably in structure (3). However, other findings suggest that at least three components of acetylcholine receptors are present in the electric tissue of torpedo californica (35) and two components of acetylcholine receptors in torpedo marmorata (7) . It cannot be excluded that in certain CNS locations in humans, receptors to specific neurotransmitters may be heterogenous, but even if the receptors themselves are homogenous, an antibody to the receptor site and to the adjacent 600 A 2 -1900 A 2 may specifically and selectively bind to some of the receptors only, for example, the receptors in a certain specific CNS area. It is postulated that even if the receptors are homogenous, their adjacent area may be heterogenous and that this heterogenicity can be used for the partial specific binding and neutralization by antibodies.
Obviously, the possible therapeutic use of antibodies to receptors will depend, among other factors, on their localization in theCNS.
As mentioned, there is a blood-CSF barrier to immunoglobulins (9, 41) but, once in the CSF, antibodies are expected to reach the CNS inasmuch as the CSF-CNS barrier is permeable to macromolecules (6, 31) .
However, administration of antibodies to the CSF may obviously have certain technical limitations and disadvantages. Another possibility is to use relatively small fractions of antibodies which can still combine with the antigenic determinant.
Fab fragments could be used (39) or even smaller fragments such as associated VLand V H segments obtainable from Fab fragments by enzymatic digestion and most of the antigenic determinant binding activity of the intact antibody molecule would be retained (12) . It is possible that such fragments of antibodies may cross the blood-CSF-CNS barrier much more effectively than the intact antibody. Whether this is indeed so is presently unknown and will have to be tested experimentally.
It is possible that such fragments of heterogenous antibody will not be as immunogenic as the intact antibody and, therefore, less likely to cause damage to the recipient of heterologous antibodyfragments.
Work by Heath et ai. (18, 19, 20) suggests that schizophrenia may be an autoimmune disease. Even though the autoimmune theory of schizophrenia is controversial, further work to elucidate the possible implication of autoimmunemechanism in the etiology of schizophrenia is warranted.
In other autoimmune processes affecting the CNS, such as experimental allesgic encephalomyelitis (EAEM), pathogenic and protective antibodies may be involved in the active (21) and recovery phase (29) of the disease process, respectively. In EAEM, pathogenic antibodies in the rhesus monkey were of the IgG class (21) and protective antibodies in rats were IgM immunoglobulins (29) .
According to Heath et ai. (18, 19, 20) , taraxein is an IgG autoantibody against the septal region, and they reported that taraxein can be fractionated from certain schizophrenics while they are acutely psychotic. Considerations should be given to the possibility that 'protective' antibodies may have an opposite therapeutic function in schizophrenic remission. If they were different in physical properties from the cytotoxic antibodies, they could be separated by available methods and administered to acutely psychotic schizophrenics. Another possibility would be to administer plasma from a schizophrenic in remission to schizophrenics in acute relapse, and evaluate whether such a procedure has any therapeutic effects.
Another possible therapeutic use of antibodies is as a neutralizer of activity of an enzyme which is overactive and is causing an undesirable behavioural effect by its enhanced activity. Antibodies specific against enzymes can block the biological activity of the respective enzyme (I).
It is believed that the stress involved in depressive illness may induce liver pyrrolase and thus shift the metabolism of tryptophane towards the kynurenine pathway, and lead to decreased levels of serotonin and to further exacerbation of the depressive illness, in a vicious circle manner (34) .
Similarly, indolethylamine-N-methyltransferase may be implicated in the etiology of schizophrenia (26, 47) . Conceivably, fragments of antibodies specific to pyrrolase and indolethylamine-N-methyltransferase could be used in the treatment of depression and schizophrenia, respectively.
Intact antibodies may not reach the intracellular site where the respective enzymes are located. It is possible that fragments of antibodies, for example, associated VH and VL segments (12) may reach the intracellular localization of the respective enzymes. As mentioned, the use of fragments, rather than intact antibodies, may reduce immunogenicity of the heterologous antibody in the recipient.
Further development of methods for the induction of immunological tolerance which would prevent the undesirable effects of heterologous antibody protein may increase the feasibility of such immunological approaches in treatment. Several methods for the induction of immunological tolerance to heterologous protein have been established: for example, by administration of an ultracentrifuged soluble fraction of the heterologous protein to the recipient (11) .
There is a possibility that some or all of the immunological treatment methods proposed in the present paper may induce autoimmune processes in the recipient. This possibility will have to be investigated by animal experiments.
It should be noted that antibodies may belong to various subclasses of specific immunoglobulins (5) .
Summary
The possible use of immunological methods in the treatment of certain psychiatric disorders is discussed. The potential advantages of such methods, the potential risks involved and the difficulties which may be encountered in the development of such methods are also discussed. The following hypotheses are proposed:
• Active immunization with immunogenic conjugates of psychotomimetic small molecules with haptenic properties and with immunogenic proteins implicated in the etiology of schizophrenia may be used in the treatment of that disorder.
• Antibodies against enzymes, such as indolethylamine-N-methyltransferase, may have therapeutic use.
• Antibodies against post-synaptic membranes may be used as specific blockers of neurotransmitter receptors.
• 'Protecting' antibodies may have a therapeutic effect in certain schizophrenics.
• Active immunization with immunogenic conjugates of narcotics may be used as narcotic-antagonists. This paper was not written with the aim of recommending the premature clinical use of immunological methods in the treatment of psychiatric disorders, but, rather, with the hope that it may stimulate further basic research in this potentially promising but difficult field.
